Moderna, Inc. — Director's Dealing 2018

Dec 7, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2018-12-07

Reporting Person: Slaoui Moncef (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$11.93	2027-08-30	Common Stock (42201)		Direct
Stock Option (Right to Buy)	$14.22	2028-02-28	Common Stock (40307)		Direct

Footnotes

F1: This option is fully vested and exercisable.

F2: This option will be fully vested and exercisable on February 28, 2019.